866-997-4948(US-Canada Toll Free)

Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline Review, H1 2014

Published By :

Global Markets Direct

Published Date : May 2014

Category :

Cancer

No. of Pages : 60 Pages


Global Markets Directs, Adrenocortical Carcinoma (Adrenal Cortex Cancer) Pipeline Review, H1 2014, provides an overview of the Adrenocortical Carcinoma (Adrenal Cortex Cancer)s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Adrenocortical Carcinoma (Adrenal Cortex Cancer), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Adrenocortical Carcinoma (Adrenal Cortex Cancer) and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.


Scope

  • The report provides a snapshot of the global therapeutic landscape of Adrenocortical Carcinoma (Adrenal Cortex Cancer)
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
  • The report reviews key players involved in the therapeutics development for Adrenocortical Carcinoma (Adrenal Cortex Cancer) and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects 
  • A review of the Adrenocortical Carcinoma (Adrenal Cortex Cancer) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Adrenocortical Carcinoma (Adrenal Cortex Cancer) pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Adrenocortical Carcinoma (Adrenal Cortex Cancer)
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Adrenocortical Carcinoma (Adrenal Cortex Cancer) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents

Table of Contents 2

List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Adrenocortical Carcinoma (Adrenal Cortex Cancer) Overview 6
Therapeutics Development 7
Pipeline Products for Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Overview 7
Pipeline Products for Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Comparative Analysis 8
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Therapeutics under Development by Companies 9
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Products under Development by Companies 13
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Companies Involved in Therapeutics Development 14
Amgen Inc. 14
Tekmira Pharmaceuticals Corp. 15
Pfizer Inc. 16
INSYS Therapeutics, Inc. 17
Ascenta Therapeutics, Inc. 18
Orphagen Pharmaceuticals, Inc. 19
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 24
Assessment by Route of Administration 27
Assessment by Molecule Type 29
Drug Profiles 31
axitinib - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
AT-101 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
cintredekin besudotox - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
TKM-PLK1 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
ATR-101 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
AMG-900 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Steroidogenic Factor-1 Antagonists - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Recent Pipeline Updates 48
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Dormant Projects 54
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Discontinued Products 55
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Product Development Milestones 56
Featured News & Press Releases 56
Oct 15, 2013: Atterocor Announces Initiation of Phase 1 Clinical Trial of ATR-101 in Adrenocortical Carcinoma 56
Oct 08, 2013: Tekmira Provides Corporate Update On Oncology Product Candidate TKM-PLK1 56
Aug 12, 2013: Tekmira commences Phase I/II study of TKM-PLK1 58

Appendix 59
Methodology 59
Coverage 59
Secondary Research 59
Primary Research 59
Expert Panel Validation 59
Contact Us 60
Disclaimer 60

List of Table

Number of Products under Development for Adrenocortical Carcinoma (Adrenal Cortex Cancer), H1 2014 7
Number of Products under Development for Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 10
Comparative Analysis by Clinical Stage Development, H1 2014 11
Comparative Analysis by Early Stage Development, H1 2014 12
Products under Development by Companies, H1 2014 13
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Amgen Inc., H1 2014 14
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Tekmira Pharmaceuticals Corp., H1 2014 15
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Pfizer Inc., H1 2014 16
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by INSYS Therapeutics, Inc., H1 2014 17
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Ascenta Therapeutics, Inc., H1 2014 18
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Orphagen Pharmaceuticals, Inc., H1 2014 19
Assessment by Monotherapy Products, H1 2014 20
Number of Products by Stage and Target, H1 2014 23
Number of Products by Stage and Mechanism of Action, H1 2014 26
Number of Products by Stage and Route of Administration, H1 2014 28
Number of Products by Stage and Molecule Type, H1 2014 30
Adrenocortical Carcinoma (Adrenal Cortex Cancer) Therapeutics - Recent Pipeline Updates, H1 2014 48
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Dormant Projects, H1 2014 54
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Discontinued Products, H1 2014 55


List of Chart



Number of Products under Development for Adrenocortical Carcinoma (Adrenal Cortex Cancer), H1 2014 7
Number of Products under Development for Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Comparative Analysis by Clinical Stage Development, H1 2014 11
Assessment by Monotherapy Products, H1 2014 20
Number of Products by Top 10 Target, H1 2014 21
Number of Products by Stage and Top 10 Target, H1 2014 22
Number of Products by Top 10 Mechanism of Action, H1 2014 24
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 25
Number of Products by Top 10 Route of Administration, H1 2014 27
Number of Products by Stage and Top 10 Route of Administration, H1 2014 28
Number of Products by Top 10 Molecule Type, H1 2014 29
Number of Products by Stage and Top 10 Molecule Type, H1 2014 30

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *